Valuation : Gossamer Bio

Market Cap 69.61M 59.87M 56.49M 51.46M 96.19M 6.66B 97.07M 673M 259M 3.38B 261M 256M 10.72B P/E 2026 *
-0.7x
P/E 2027 * -0.71x
Enterprise Value 79.91M 68.72M 64.84M 59.07M 110M 7.64B 111M 772M 297M 3.88B 300M 294M 12.31B EV / Sales 2026 *
2.23x
EV / Sales 2027 * -5.58x
Free-Float
98.48%
Yield 2026 *
-
Yield 2027 * -
1 day-10.83%
1 week-98.99%
Current month-98.95%
1 month-98.99%
3 months-98.86%
6 months-99.65%
Current year-99.94%
1 week 0.14
Extreme 0.1402
14.75
1 month 0.14
Extreme 0.1402
17.1
Current year 0.14
Extreme 0.1402
252
1 year 0.14
Extreme 0.1402
309.6
3 years 0.14
Extreme 0.1402
309.6
5 years 0.14
Extreme 0.1402
1,215.6
10 years 0.14
Extreme 0.1402
2,171.98
Manager TitleAgeSince
Chief Executive Officer 67 2020-11-15
Director of Finance/CFO 50 2018-05-06
Chief Tech/Sci/R&D Officer 66 2021-05-31
Director TitleAgeSince
Chairman 67 2015-10-25
Director/Board Member 72 2017-12-31
Director/Board Member 62 2018-12-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/24/26 Free

Chief Financial Officer

5,800,076 1.1865%
8/24/26 Free

General Counsel

2,900,026 0.5932%
8/24/26 Free

Executive/Senior Manager

5,800,051 1.1865%
Change 5-day change 1-year change 3-year change Capi.($)
-10.83%-98.99%-99.94%-99.82% 69.61M
+0.36%-5.25%-3.76%+10.30% 46.05B
-2.08%-3.57%+402.72%+533.09% 43.59B
+0.12%-5.27%+39.94%+20.50% 42.35B
-2.62%-5.76%+8.88%+77.44% 38.86B
-1.26%-3.37%+11.87%+40.55% 32.24B
+0.16%-3.65% - - 17.16B
-0.54%-1.72%+22.34%+115.10% 16.28B
+0.34%-2.15%+11.19%+31.34% 14.32B
-1.92%-6.94%+78.12%+36.68% 13.03B
Average -1.83%-6.12%+52.37%+85.02% 26.39B
Weighted average by Cap. -0.91%-5.05%+86.44%+128.40%

Financials

2026 *2027 *
Net sales 35.86M 30.84M 29.1M 26.51M 49.55M 3.43B 50M 347M 133M 1.74B 135M 132M 5.52B 20M 17.2M 16.23M 14.78M 27.63M 1.91B 27.88M 193M 74.37M 970M 75.09M 73.45M 3.08B
Net income -85.41M -73.46M -69.31M -63.14M -118M -8.17B -119M -825M -318M -4.14B -321M -314M -13.16B -117M -100M -94.55M -86.14M -161M -11.14B -162M -1.13B -433M -5.65B -438M -428M -17.95B
Net Debt 10.3M 8.86M 8.36M 7.61M 14.23M 985M 14.36M 99.54M 38.31M 499M 38.68M 37.83M 1.59B -181M -156M -147M -134M -250M -17.31B -253M -1.75B -674M -8.78B -680M -665M -27.89B
Logo Gossamer Bio
Gossamer Bio, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The Company's lead product candidate is Seralutinib (GB002), is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR. Seralutinib is designed to inhibit multiple kinases in the pathology of PAH. The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. The c-KIT pathway was also identified as a factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation.
Employees
162
Date Price Change Volume
26-09-10 US$11.39 -10.83% 165,331
26-09-09 US$12.78 -11.23% 296,180
26-09-08 US$14.39 +2.62% 86,487
26-09-04 US$14.02 -0.17% 101,166
26-09-03 US$14.05 +1.68% 71,621
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.39USD
Average target price
132.48USD
Spread / Average Target
+1,062.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GOSS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!